Download PDF
Dtsch Med Wochenschr 2021; 146(04): 287-291
DOI: 10.1055/a-1273-1657
Übersicht

Von der Neuroendokrinologie zu den Volkskrankheiten in der Inneren Medizin[*]

From neuroendocrinology to widespread diseases in internal medicine
Henrik Oster
,
Jens Mittag
,
Sebastian M. Schmid
› Further Information
Also available at
    Permissions and Reprints

Die Innere Medizin in der Vielfalt ihrer Subdisziplinen zu verstehen und zu leben [1] ist der Anspruch, den Herr Prof. Dr. Dr. h. c. Hendrik Lehnert an sich und an seine Mitarbeiter stellt. Sein Vorgehen in der täglichen Praxis orientiert sich dabei stets an den aktuellen Erkenntnissen der Wissenschaft – im besten Wortsinn einer translationalen Medizin. Wir widmen ihm diesen Beitrag, wohlwissend, dass sein Wirken sowie seine Empathie für Patienten und Mitarbeiter nur schlaglichtartig skizziert werden können.

Schlüsselwörter

Neuroendokrinologie - Neuroendokrine Neoplasie - Phäochromozytom - Chronobiologie - Diabetes - Adipositas - Adipokine

Key words

neuroendocrinology - neuroendocrine tumor - pheochromocytoma - chronobiology - diabetes - obesity - adipokine

* Gewidmet Herrn Prof. Dr. med. Hendrik Lehnert anlässlich seiner Verabschiedung als DMW-Herausgeber.




Publication History

Article published online:
16 February 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Ertl G, Lehnert H. [Internal medicine is more than the sum of its subspecialties]. Dtsch Med Wochenschr 2011; 136 (14) 671
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Lehnert H, Kaluza K, Vetter H. et al. Long-term effects of a complex behavioral treatment of essential hypertension. Psychosom Med 1987; 49 (04) 422-230
    CrossrefPubMedGoogle Scholar
  • 3 Lehnert H, Beyer J, Cloer E. et al. Effects of l-tryptophan and various diets on behavioral functions in essential hypertensives. Neuropsychobiology 1989; 21 (02) 84-89
    CrossrefPubMedGoogle Scholar
  • 4 Kreutz M, Hellhammer D, Murison R. et al. Pavlovian conditioning of corticotropin-releasing factor-induced increase of blood pressure and corticosterone secretion in the rat. Acta Physiol Scand 1992; 145 (01) 59-63
    CrossrefPubMedGoogle Scholar
  • 5 Kübler A, Rothacher G, Knappertz VA. et al. Intra- and extracerebral blood flow changes and flushing after intravenous injection of human corticotropin-releasing hormone. Clin Investig 1994; 72 (05) 331-336
    CrossrefPubMedGoogle Scholar
  • 6 Nink M, Salomon E, Coutinho M. et al. Corticotropin-releasing hormone (CRH) is a respiratory stimulant in humans: a comparative study of human and ovine CRH. Life Sci 1994; 54 (23) 1793-1799
    CrossrefPubMedGoogle Scholar
  • 7 Rohrer T, von Richthofen V, Schulz C. et al. The stress-, but not corticotropin-releasing hormone-induced activation of the pituitary-adrenal axis in man is blocked by alprazolam. Horm Metab Res Horm Stoffwechselforschung Horm Metab 1994; 26 (04) 200-206
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Kopf D, Bockisch A, Steinert H. et al. Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma. Clin Endocrinol (Oxf) 1997; 46 (01) 39-44
    CrossrefPubMedGoogle Scholar
  • 9 Hollenbach E, Schulz C, Lehnert H. Rapid and sensitive determination of catecholamines and the metabolite 3-methoxy-4-hydroxyphen-ethyleneglycol using HPLC following novel extraction procedures. Life Sci 1998; 63 (09) 737-750
    CrossrefPubMedGoogle Scholar
  • 10 Boltze C, Mundschenk J, Unger N. et al. Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma. J Clin Endocrinol Metab 2003; 88 (09) 4280-4286
    CrossrefPubMedGoogle Scholar
  • 11 Mundschenk J, Unger N, Schulz S. et al. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab 2003; 88 (11) 5150-5157
    CrossrefPubMedGoogle Scholar
  • 12 Scholz T, Eisenhofer G, Pacak K. et al. Clinical review: Current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 2007; 92 (04) 1217-1225
    CrossrefPubMedGoogle Scholar
  • 13 Parving HH, Lehnert H, Bröchner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345 (12) 870-878
    CrossrefPubMedGoogle Scholar
  • 14 Ambrosch A, Mühlen I, Kopf D. et al. LDL size distribution in relation to insulin sensitivity and lipoprotein pattern in young and healthy subjects. Diabetes Care 1998; 21 (12) 2077-2084
    CrossrefPubMedGoogle Scholar
  • 15 Zhang Y, Proenca R, Maffei M. et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432
    CrossrefPubMedGoogle Scholar
  • 16 Oh-I S, Shimizu H, Satoh T. et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006; 443: 709-712
    CrossrefPubMedGoogle Scholar
  • 17 Ramanjaneya M, Chen J, Brown JE. et al. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology 2010; 151 (07) 3169-3180
    CrossrefPubMedGoogle Scholar
  • 18 Tan BK, Hallschmid M, Kern W. et al. Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/NUCB-2, in obese humans: evidence of nesfatin-1/NUCB-2 resistance and implications for obesity treatment. J Clin Endocrinol Metab 2011; 96 (04) E669-E673
    CrossrefPubMedGoogle Scholar
  • 19 Wernecke K, Lamprecht I, Jöhren O. et al. Nesfatin-1 increases energy expenditure and reduces food intake in rats. Obesity 2014; 22 (07) 1662-1668
    CrossrefPubMedGoogle Scholar
  • 20 Hallschmid M, Higgs S, Thienel M. et al. Postprandial administration of intranasal insulin intensifies satiety and reduces intake of palatable snacks in women. Diabetes 2012; 61 (04) 782-789
    CrossrefPubMedGoogle Scholar
  • 21 Levata L, Dore R, Jöhren O. et al. Nesfatin-1 Acts Centrally to Induce Sympathetic Activation of Brown Adipose Tissue and Non-Shivering Thermogenesis. Horm Metab Res 2019; 51 (10) 678-685
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Dore R, Levata L, Gachkar S. et al. The thermogenic effect of nesfatin-1 requires recruitment of the melanocortin system. J Endocrinol 2017; 235 (02) 111-122
    CrossrefPubMedGoogle Scholar
  • 23 Dore R, Krotenko R, Reising JP. et al. Nesfatin-1 decreases the motivational and rewarding value of food. Neuropsychopharmacology 2020; 45 (10) 1645-1655
    CrossrefPubMedGoogle Scholar
  • 24 Hallschmid M, Randeva H, Tan BK. et al. Relationship between cerebrospinal fluid visfatin (PBEF/Nampt) levels and adiposity in humans. Diabetes 2009; 58 (03) 637-640
    CrossrefPubMedGoogle Scholar
  • 25 Barclay JL, Husse J, Bode B. et al. Circadian Desynchrony Promotes Metabolic Disruption in a Mouse Model of Shiftwork. PLoS One 2012; 7 (05) e37150
    CrossrefPubMedGoogle Scholar
  • 26 Husse J, Hintze SC, Eichele G. et al. Circadian clock genes Per1 and Per2 regulate the response of metabolism-associated transcripts to sleep disruption. PloS One 2012; 7 (12) e52983
    CrossrefPubMedGoogle Scholar
  • 27 Husse J, Kiehn JT, Barclay JL. et al. Tissue-Specific Dissociation of Diurnal Transcriptome Rhythms During Sleep Restriction in Mice. Sleep 2017; 40 (06) zsx068
    CrossrefPubMedGoogle Scholar
  • 28 Pagel R, Bär F, Schröder T. et al. Circadian rhythm disruption impairs tissue homeostasis and exacerbates chronic inflammation in the intestine. FASEB J Off Publ Fed Am Soc Exp Biol 2017; 31 (11) 4707-4719
    PubMedGoogle Scholar
  • 29 Wilms B, Leineweber EM, Mölle M. et al. Sleep loss disrupts morning-to-evening differences in human white adipose tissue transcriptome. J Clin Endocrinol 2018; 21: 1687-1696
    PubMedGoogle Scholar
  • 30 Monk TH, Buysse DJ, Billy BD. et al. Shiftworkers report worse sleep than day workers, even in retirement. J Sleep Res 2013; 22 (02) 201-208
    CrossrefPubMedGoogle Scholar
  • 31 Schmid SM, Hallschmid M, Jauch-Chara K. et al. Partial sleep restriction modulates secretory activity of thyrotropic axis in healthy men. J Sleep Res 2013; 22 (02) 166-169
    CrossrefPubMedGoogle Scholar
  • 32 Wilms B, Chamorro R, Hallschmid M. et al. Timing Modulates the Effect of Sleep Loss on Glucose Homeostasis. J Clin Endocrinol Metab 2019; 104 (07) 2801-2808
    CrossrefPubMedGoogle Scholar
  • 33 Wilms B, Kuhr M, Chamorro R. et al. Chronobiological aspects of sleep restriction modulate subsequent spontaneous physical activity. Physiol Behav 2020; 215: 112795
    CrossrefPubMedGoogle Scholar
  • 34 Sun M, Feng W, Wang F. et al. Meta-analysis on shift work and risks of specific obesity types. Obes Rev Off J Int Assoc Study Obes 2018; 19 (01) 28-40
    CrossrefPubMedGoogle Scholar
  • 35 Potter GDM, Skene DJ, Arendt J. et al. Circadian Rhythm and Sleep Disruption: Causes, Metabolic Consequences, and Countermeasures. Endocr Rev 2016; 37 (06) 584-608
    CrossrefPubMedGoogle Scholar
  • 36 Ruud J, Alber J, Tokarska A. et al. The Fat Mass and Obesity-Associated Protein (FTO) Regulates Locomotor Responses to Novelty via D2R Medium Spiny Neurons. Cell Rep 2019; 27 (11) 3182-3198.e9
    CrossrefPubMedGoogle Scholar
  • 37 Tiedemann LJ, Schmid SM, Hettel J. et al. Central insulin modulates food valuation via mesolimbic pathways. Nat Commun 2017; 8: 16052
    CrossrefPubMedGoogle Scholar
  • 38 Timper K, Denson JL, Steculorum SM. et al. IL-6 Improves Energy and Glucose Homeostasis in Obesity via Enhanced Central IL-6 trans-Signaling. Cell Rep 2017; 19 (02) 267-2680
    CrossrefPubMedGoogle Scholar
  • 39 Koch CE, Begemann K, Kiehn JT. et al. Circadian regulation of hedonic appetite in mice by clocks in dopaminergic neurons of the VTA. Nat Commun 2020; 11 (01) 3071
    CrossrefPubMedGoogle Scholar